Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor

Journal of Neurochemistry
Daniel KomnigBjörn H Falkenburger

Abstract

Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons and aggregates of α-synuclein termed Lewy bodies. Fingolimod (FTY720) is an agonist of sphingosine-1 phosphate receptors and an approved oral treatment for multiple sclerosis. Fingolimod elevates brain-derived neurotrophic factor (BDNF), an important neurotrophic factor for dopaminergic neurons. BDNF and fingolimod are beneficial in several animal models of PD. In order to validate the therapeutic potential of fingolimod for the treatment of PD, we tested its effect in the subacute MPTP mouse model of PD. MPTP or vehicle was applied i.p. in doses of 30 mg/kg MPTP on five consecutive days. In order to recapitulate the combination of dopamine loss and α-synuclein aggregates found in PD, MPTP was first administered in Thy1-A30P-α-synuclein transgenic mice. Fingolimod was administered i.p. at a dose of 0.1 mg/kg every second day. Nigrostriatal degeneration was assayed by stereologically counting the number of dopaminergic neurons in the substantia nigra pars compacta, by analysing the concentration of catecholamines and the density of dopaminergic fibres in the striatum. MPTP administration produced a robust nigrostriatal degeneration, comparable...Continue Reading

References

Sep 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·V Jackson-LewisS Przedborski
Jul 25, 2000·Journal of Neural Transmission·R K PearceC D Marsden
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Dec 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sebastian KowskyJörg B Schulz
Oct 23, 2009·Journal of Neurology·Paula ScalzoAntônio Lúcio Teixeira
Dec 24, 2010·Proceedings of the National Academy of Sciences of the United States of America·Ji Woong ChoiJerold Chun
Nov 17, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anja DrinkutSebastian Kügler
Dec 23, 2011·Parkinsonism & Related Disorders·Vernice Jackson-LewisSerge Przedborski
Aug 15, 2012·Proceedings of the National Academy of Sciences of the United States of America·Rubén DeograciasYves-Alain Barde
Jan 1, 2011·Journal of Parkinson's Disease·Gloria E Meredith, David J Rademacher
May 4, 2013·Parkinsonism & Related Disorders·Asako YoritakaNobutaka Hattori
Jul 22, 2014·Annals of Neurology·Emanuela ColomboCinthia Farina
Aug 2, 2014·Journal of Neuroimmunology·Stine MenclChristoph Kleinschnitz
Aug 22, 2015·Journal of Neural Transmission·Heinz Reichmann
Apr 20, 2016·Journal of Neurochemistry·Björn H FalkenburgerElisabeth Dinter
Sep 1, 2016·Journal of Neurochemistry·Wolfgang Oertel, Jörg B Schulz
Sep 18, 2016·Journal of Neurochemistry·Daniel KomnigBjörn H Falkenburger
Sep 28, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Peng ZhaoXiaodong Zhu
Nov 9, 2016·Neuropharmacology·Sinead O'Sullivan, Kumlesh K Dev
Sep 10, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·J A ObesoA J Stoessl

❮ Previous
Next ❯

Citations

Jul 23, 2020·Drugs in R&D·Pablo BascuñanaJens Pahnke
Aug 21, 2019·Frontiers in Pharmacology·Sara GrassiPaola Giussani
Jan 7, 2019·Molecular Neurobiology·Kinga CzubowiczRobert P Strosznajder
Jul 3, 2021·International Journal of Molecular Sciences·Joanna A MotylRobert P Strosznajder
Dec 15, 2021·The European Journal of Neuroscience·Wenjing ShenYingzhu Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.